Nowadays, most CF therapies focus on treating secondary pulmonary complications, and the importance of targeting TGF-β as a cytokine involved in fibrosis, inflammation, and injury response has already been reported in the literature [43]. The gene discussed is TGFB1; the disease is cystic fibrosis.